DPYSL2 and amyotrophic lateral sclerosis: There are at least two additional pieces of evidence besides Verrhaagen's finding to suggest that the Sema3A-CRMP2-cytoskeleton signaling pathway is involved at least in murine ALS and potentially amenable to pharmacological intervention.